Index Ventures launches EUR150m life sciences fund
Venture capital firm Index Ventures has launched new EUR150m life sciences fund which includes investments from GlaxoSmithKline and the venture capital affiliate of the Janssen pharmaceutical companies of Johnson & Johnson alongside Index's existing limited partners.
Assets under management in the European fund industry could reach EUR6.8trn by 2014, according to a study published by Alfi, the Association of the Luxembourg Fund Industry, and produced by Lipper FMI.